Expand CGEM Menu
CGEM MENU

CGEM Latest Press Releases

-- October 8, 2026 --

Cullinan Therapeutics Announces First Patient Dosed in Planned Registrational Phase 2 Study of CLN-049 in Relapsed/Refractory Acute Myeloid Leukemia Globe Newswire 7:00 AM

-- October 1, 2026 --

New Drug Application Submission Initiated for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation NSCLC for Review Under FDA Real-Time Oncology Review Program Globe Newswire 7:30 PM

-- September 24, 2026 --

Cullinan Therapeutics Highlights Fourth Quarter 2026 Milestones Across Immunology and Oncology T Cell Engager Portfolio Globe Newswire 7:00 AM

-- September 21, 2026 --

Cullinan Therapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum Globe Newswire 12:00 PM

-- September 14, 2026 --

Cullinan Therapeutics to Host Virtual Analyst and Investor Event Today to Feature Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer Globe Newswire 7:00 AM

-- September 13, 2026 --

Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit in REZILIENT3 Phase 3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer Business Wire 7:15 PM

-- September 10, 2026 --

Cullinan Therapeutics to Host Virtual Analyst and Investor Event to Showcase Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer Globe Newswire 1:00 PM

-- August 19, 2026 --

Zipalertinib Plus Chemotherapy First-Line Phase 3 REZILIENT3 Trial Data Selected for Presidential Symposium Presentation at the IASLC 2026 World Conference on Lung Cancer Business Wire 12:03 PM

-- August 12, 2026 --

Zipalertinib Plus Chemotherapy Meets Primary Endpoint of Progression-Free Survival in Planned Interim Analysis of Phase 3 REZILIENT3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer Business Wire 7:30 PM

-- August 6, 2026 --

Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results Globe Newswire 7:00 AM

-- July 28, 2026 --

Cullinan Therapeutics Announces Positive End-of-Phase 1 Meeting with FDA for CLN-049 and Advances Program to a Potentially Registrational Phase 2 Study in AML Globe Newswire 7:00 AM

-- June 10, 2026 --

Cullinan Therapeutics Shares New Clinical Data Across Its Portfolio of T Cell Engager Programs Targeting CD19 and BCMA in Autoimmune Diseases Globe Newswire 7:30 AM

-- June 6, 2026 --

Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress Globe Newswire 5:15 AM

-- May 26, 2026 --

Cullinan Therapeutics to Host Immunology Day to Showcase Promising Initial Clinical Data in Autoimmune Diseases for CLN-978, a CD19 T Cell Engager, and Velinotamig, a BCMA T Cell Engager Globe Newswire 7:00 AM

-- May 19, 2026 --

Cullinan Therapeutics Receives FDA Orphan Drug Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia Globe Newswire 7:00 AM

-- May 18, 2026 --

Cullinan Therapeutics to Present Initial Clinical Data for CLN-978 in Treatment-Refractory Rheumatoid Arthritis and Systemic Lupus Erythematosus at EULAR 2026 Congress Globe Newswire 5:00 PM
The Biology Came First. Business Wire 8:34 AM
Market Data Delayed 15 Minutes